DCBLD1 Promotes Lung Tumorigenesis by Inhibiting PTP1B Dephosphorylation of EGFR

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Lung adenocarcinoma (LUAD) pathogenesis involves complex molecular events.
• Discoidin, CUB and LCCL domain containing 1 (DCBLD1) was previously identified as a novel LUAD risk gene.

Purpose of the Study:

• To investigate the function and mechanisms of DCBLD1 in LUAD progression.
• To explore DCBLD1 as a potential therapeutic target for LUAD.

Main Methods:

• Overexpression and deficiency studies in bronchial epithelial cells and DCBLD1-/- mice.
• Mechanistic studies involving DCBLD1 interaction with EGFR and PTP1B.
• Assessment of downstream signaling pathways (PI3K/AKT, MAPK).
• Therapeutic evaluation using patient-derived organoids and xenograft models.

Main Results:

• DCBLD1 overexpression promotes cellular transformation and LUAD initiation.
• DCBLD1 interacts with EGFR, displacing PTP1B and causing sustained EGFR activation.
• DCBLD1 knockdown exhibits significant antitumor effects in preclinical models.
• Therapeutic efficacy is independent of EGFR mutation status.

Conclusions:

• DCBLD1 is a key oncogenic driver in LUAD through EGFR pathway dysregulation.
• DCBLD1 represents a promising therapeutic target for LUAD treatment.
• Targeting DCBLD1 offers a strategy complementary to existing EGFR-targeted therapies.